FDA-approved
Brain & sleep
Trofinetide
Evidence
FDA approved
Class
Synthetic analog of an IGF-1 fragment
KEY TAKEAWAY
Trofinetide is a small synthetic peptide based on a fragment of insulin-like growth factor 1 (IGF-1). It is sold as Daybue. The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.
Written by the Veylo editorial team · Updated
November 2026
What it is
Synthetic analog of an IGF-1 fragment
Approved for
Rett syndrome in children and adults aged 2 and older
Key fact
The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.
Route
Oral solution taken twice a day
Evidence strength
FDA approved
Trofinetide is a small synthetic peptide based on a fragment of insulin-like growth factor 1 (IGF-1). It is sold as Daybue.
It is thought to reduce inflammation and support the connections between nerve cells. How it helps in Rett syndrome is not fully understood.
The FDA approved trofinetide (Daybue) in March 2023 for Rett syndrome in adults and children aged 2 and older.
Rett syndrome in children and adults aged 2 and older.
Diarrhea and vomiting are the most common side effects. They can cause dehydration or weight loss in some people.
U.S. FDA prescribing information for Trofinetide. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.